 GENEVA, SWITZERLAND ACCESSWIRE October 15, 2021 RELIEF THERAPEUTICS Holding SA SIX:RLF, OTCQB:RLFTF Relief , a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc. Nasdaq: NRXP NRx , has issued a press release announcing that the peer-reviewed Journal of Infectious Diseases and Treatment has published positive trial data from a prospective, open label, administratively controlled trial of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. According to the press release, the study reported 60-day survival in 81 of those treated with aviptadil, compared to 21 survival among those who received standard of care treatment at the Houston Methodist Hospital P 